alnylam
"alnylam" is a word mark owned by Alnylam Pharmaceuticals, Inc., filed at the IPOS on August 1, 2018. It is registered and covers class 5 (Pharmaceuticals).
- Status
- Registered
- Since August 1, 2018
- Filed
- August 1, 2018
- Registered
- February 22, 2019
- Expires
- August 1, 2028
- Application no.
- 40201815071W
- Registration no.
- 40201815071W
- Office
- IPOS
- Intellectual Property Office of Singapore
- Mark type
- Word mark
- 1 class
Who owns alnylam
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Alnylam Pharmaceuticals, Inc.
ALNY · United States
Representative
Allen & Gledhill LLP
Allen & Gledhill LLP
What the mark covers
The products and services alnylam is filed for, grouped by Nice class.
Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceutical preparations, namely, RNA therapeutics; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes
What has happened so far
Steps recorded by the IPOS, newest first.
- Registration procedure completed
- Application filed
About alnylam
Who owns the trademark "alnylam"?
The IPOS trademark "alnylam" (application 40201815071W) is owned by Alnylam Pharmaceuticals, Inc.
What is the status of "alnylam"?
Its status at the IPOS is: registered.
When was "alnylam" registered?
It was registered on February 22, 2019 and is due to expire on August 1, 2028.
Get this data via the API
Everything on this page comes from the Signa API. Pull alnylam and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019df6aa-cddf-7218-9cd9-2efdbb4b96f6
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019df6aa-cddf-7218-9cd9-2efdbb4b96f6",
"object": "trademark",
"mark_text": "alnylam",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "SG",
"application_number": "40201815071W",
"filing_date": "2018-08-01",
"nice_classes": [
5
],
"owners": [
{
"name": "Alnylam Pharmaceuticals, Inc.",
"entity_id": "ent_019eb709-7d9a-70dc-b19d-2c56e8a223b5"
}
]
}